Meeting
2023 ASCO Genitourinary Cancers Symposium
Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.
Authors
Jun Gong
Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
Jun Gong , Jessica Janes , Anoruo Asilonu , Claire Trustram Eve , Shannon R. Stock , Justin Waller , Amanda Marie De Hoedt , Jeri Kim , Sameer R. Ghate , Irene M Shui , Stephen J. Freedland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 92)
DOI
10.1200/JCO.2023.41.6_suppl.92
Abstract #
92
Poster Bd #
C15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC).
First Author: Praful Ravi
Poster
2024 ASCO Genitourinary Cancers Symposium
ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer.
First Author: Giulio Francolini
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans
Poster
2024 ASCO Genitourinary Cancers Symposium
Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christopher Sweeney